Orforglipron (LY-3502970) vs VIP (Vasoactive Intestinal Polypeptide)
Updated October 27, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Orforglipron (LY-3502970) and VIP (Vasoactive Intestinal Polypeptide) (also searched as VIP (Vasoactive Intestinal Polypeptide) vs Orforglipron (LY-3502970)) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Orforglipron (LY-3502970) centers on metabolic, while VIP (Vasoactive Intestinal Polypeptide) leans toward neuro. On indexed research, VIP (Vasoactive Intestinal Polypeptide) is ahead (Orforglipron (LY-3502970): 36 studies, Human clinical; VIP (Vasoactive Intestinal Polypeptide): 44, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Orforglipron (LY-3502970) is strongest for metabolic; VIP (Vasoactive Intestinal Polypeptide) for neuro.
- •Evidence: Orforglipron (LY-3502970) Human clinical (36 studies) vs VIP (Vasoactive Intestinal Polypeptide) Human clinical (44).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
GLP-1 Agonist | Type 2 Diabetes and Obesity
Neuropeptide | Gastrointestinal regulation
Orforglipron (LY-3502970) vs VIP (Vasoactive Intestinal Polypeptide): side-by-side
| Metric | Orforglipron (LY-3502970) | VIP (Vasoactive Intestinal Polypeptide) |
|---|---|---|
| Class | Metabolic | Neuro |
| Regulatory status | FDA-approved | Research use only |
| Evidence grade | Human clinical | Human clinical |
| Studies indexed | 36 | 44 |
| Research level | FDA Approved | Well Studied |
| Strongest effect | Metabolic & appetite | Neuro & mood |
| Healing & recovery | 2.0▲ | 2.0▲ |
| Muscle & body comp | 1.0▲ | 1.0▲ |
| Metabolic & appetite | 5.0▲ | 2.0 |
| Neuro & mood | 2.0 | 4.0▲ |
| Sleep & circadian | 2.0 | 3.0▲ |
| Inflammation & immune | 3.0▲ | 3.0▲ |
| Skin & aesthetics | 3.0▲ | 1.0 |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Orforglipron (LY-3502970) | VIP (Vasoactive Intestinal Polypeptide) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | VPAC1 and VPAC2 receptor agonist |
| Route | Oral | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Orforglipron (LY-3502970)?
Orforglipron (LY-3502970) is an investigational oral small-molecule GLP-1 receptor agonist studied for type 2 diabetes and obesity, offering pill-based dosing without injection.
Full Orforglipron (LY-3502970) profile, mechanism & studies →What is VIP (Vasoactive Intestinal Polypeptide)?
Vasoactive Intestinal Peptide | Neuropeptide
Full VIP (Vasoactive Intestinal Polypeptide) profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Even | Both ~2.0/5 |
| Muscle | Even | Both ~1.0/5 |
| Metabolic | Orforglipron (LY-3502970) | 5.0/5 effect signal |
| Neuro | VIP (Vasoactive Intestinal Polypeptide) | 4.0/5 effect signal |
| Sleep | VIP (Vasoactive Intestinal Polypeptide) | 3.0/5 effect signal |
| Inflammation | Even | Both ~3.0/5 |
| Skin | Orforglipron (LY-3502970) | 3.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Orforglipron (LY-3502970) and VIP (Vasoactive Intestinal Polypeptide)?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Orforglipron (LY-3502970) vs VIP (Vasoactive Intestinal Polypeptide): side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Orforglipron (LY-3502970) has 36 approved studies indexed (Human clinical), and VIP (Vasoactive Intestinal Polypeptide) has 44 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Orforglipron (LY-3502970) or VIP (Vasoactive Intestinal Polypeptide) better?
It depends on your goal. Orforglipron (LY-3502970) is strongest for metabolic; VIP (Vasoactive Intestinal Polypeptide) for neuro. VIP (Vasoactive Intestinal Polypeptide) has more indexed studies (44). See the goal-by-goal breakdown above.
Is Orforglipron (LY-3502970) or VIP (Vasoactive Intestinal Polypeptide) better for weight loss?
Orforglipron (LY-3502970) shows the stronger metabolic & appetite profile (5.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is Orforglipron (LY-3502970) or VIP (Vasoactive Intestinal Polypeptide) better for muscle?
Both land close on the muscle & body-composition axis.
Which has more research, Orforglipron (LY-3502970) or VIP (Vasoactive Intestinal Polypeptide)?
Orforglipron (LY-3502970) has 36 approved studies indexed (Human clinical); VIP (Vasoactive Intestinal Polypeptide) has 44 (Human clinical). Higher counts mean more to read, not proven superiority.
Can you stack Orforglipron (LY-3502970) and VIP (Vasoactive Intestinal Polypeptide)?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Orforglipron (LY-3502970) vs VIP (Vasoactive Intestinal Polypeptide)?
Orforglipron (LY-3502970): no community-reported effects logged yet. VIP (Vasoactive Intestinal Polypeptide): none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Orforglipron (LY-3502970) or VIP (Vasoactive Intestinal Polypeptide) FDA-approved?
Orforglipron (LY-3502970) is FDA-approved. VIP (Vasoactive Intestinal Polypeptide) is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is VIP (Vasoactive Intestinal Polypeptide) better than Orforglipron (LY-3502970)?
For neuro, VIP (Vasoactive Intestinal Polypeptide) has the edge; for metabolic, Orforglipron (LY-3502970) does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed October 27, 2026.